MicroRNA Changes in Cerebrospinal Fluid After Subarachnoid Hemorrhage

Stroke - Tập 48 Số 9 - Trang 2391-2398 - 2017
Søren Bache1, Rune Skovgaard Rasmussen2, Maria Rossing3, Finn Pedersen Laigaard4, Finn Cilius Nielsen5, Kirsten Møller1
1From the Departments of Neuroanaesthesiology (S.B., K.M.) and Neurosurgery (R.R.), The Neuroscience Centre, and Centre for Genomic Medicine (S.B., M.R., F.C.N.), Rigshospitalet, and Department of Anaesthesia, Frederiksberg Hospital (F.P.L.), University of Copenhagen, Denmark.
2Rune Rasmussen From the Departments of Neuroanaesthesiology (S.B., K.M.) and Neurosurgery (R.R.), The Neuroscience Centre, and Centre for Genomic Medicine (S.B., M.R., F.C.N.), Rigshospitalet, and Department of Anaesthesia, Frederiksberg Hospital (F.P.L.), University of Copenhagen, Denmark.
3Maria Rossing From the Departments of Neuroanaesthesiology (S.B., K.M.) and Neurosurgery (R.R.), The Neuroscience Centre, and Centre for Genomic Medicine (S.B., M.R., F.C.N.), Rigshospitalet, and Department of Anaesthesia, Frederiksberg Hospital (F.P.L.), University of Copenhagen, Denmark.
4Finn Pedersen Laigaard From the Departments of Neuroanaesthesiology (S.B., K.M.) and Neurosurgery (R.R.), The Neuroscience Centre, and Centre for Genomic Medicine (S.B., M.R., F.C.N.), Rigshospitalet, and Department of Anaesthesia, Frederiksberg Hospital (F.P.L.), University of Copenhagen, Denmark.
5Finn Cilius Nielsen From the Departments of Neuroanaesthesiology (S.B., K.M.) and Neurosurgery (R.R.), The Neuroscience Centre, and Centre for Genomic Medicine (S.B., M.R., F.C.N.), Rigshospitalet, and Department of Anaesthesia, Frederiksberg Hospital (F.P.L.), University of Copenhagen, Denmark.

Tóm tắt

Background and Purpose—

Delayed cerebral ischemia (DCI) accounts for a major part of the morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). MicroRNAs (miRNAs) are pathophysiologically involved in acute cerebral ischemia. This study compared miRNA profiles in cerebrospinal fluid from neurologically healthy patients, as well as SAH patients with and without subsequent development of DCI.

Methods—

In a prospective case–control study of SAH patients treated with external ventricular drainage and neurologically healthy patients, miRNA profiles in cerebrospinal fluid were screened and validated using 2 different high-throughput real-time quantification polymerase chain reaction techniques. The occurrence of DCI was documented in patient charts and subsequently reviewed independently by 2 physicians.

Results—

MiRNA profiles from 27 SAH patients and 10 neurologically healthy patients passed quality control. In the validation, 66 miRNAs showed a relative increase in cerebrospinal fluid from SAH patients compared with neurologically healthy patients ( P <0.001); 2 (miR-21 and miR-221) showed a relative increase in SAH patients with DCI compared with those without ( P <0.05) in both the screening and validation.

Conclusions—

SAH is associated with marked changes in the cerebrospinal fluid miRNA profile. These changes could be associated to the development of DCI.

Clinical Trial Registration—

URL: http://www.clinicaltrials.gov . Unique identifier: NCT01791257.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(07)60153-6

10.1161/STROKEAHA.110.589275

10.1371/journal.pone.0047778

Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al.. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;CD000277.

10.1093/bja/aes264

10.1038/jcbfm.2010.101

10.1038/nrclinonc.2011.76

10.1093/jmcb/mjq040

10.1007/s00221-011-2925-3

10.1089/neu.2010.1481

10.1258/acb.2008.007257

10.1186/s12967-015-0505-1

10.6026/97320630001251

10.1186/gb-2009-10-6-r64

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289–300.

10.1016/j.ymeth.2012.09.015

Liu W, Chen X, Zhang Y. Effects of microRNA-21 and microRNA-24 inhibitors on neuronal apoptosis in ischemic stroke. Am J Transl Res. 2016;8:3179–3187.

10.1016/j.jns.2015.05.036

10.1016/j.bbi.2015.04.014

10.1038/jcbfm.2008.74

10.1152/physiolgenomics.00020.2014

10.1161/CIRCRESAHA.106.141986

10.3171/2016.1.JNS151454

10.1161/JAHA.116.005363

10.1042/BSR20160480

10.1227/01.NEU.0000255394.77538.BB

10.1155/2015/379071

10.1007/s12975-014-0364-8

10.1159/000351767

10.1038/nmeth.3014

10.1093/nar/gkq601